GlassScriptPhysician profile
Edward A Overton
NPI 1093753329
$3,869.97
in general payments reported to CMS, 2019-2025
36 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2020: $581 · 2021: $378 · 2022: $665 · 2023: $576 · 2024: $507 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $687.75 | 2019-2025 | Ztlido |
| Abbott Laboratories | $563.41 | 2019-2025 | Octrode, Eterna, Proclaim |
| Pfizer INC. | $311.34 | 2019-2025 | |
| Abbvie INC. | $282.07 | 2021-2025 | |
| Indivior INC. | $225.50 | 2019-2025 | Sublocade |
| Arbor Pharmaceuticals, INC. | $183.89 | 2019-2021 | |
| Orexo US, INC. | $153.21 | 2019-2024 | Zubsolv |
| Braeburn INC. | $136.29 | 2024-2025 | Brixadi |
| Assertio Therapeutics, INC. | $112.01 | 2019 | |
| Boston Scientific Corporation | $110.94 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Almatica Pharma LLC | $110.27 | 2021-2023 | Gralise |
| Forte Bio-Pharma LLC | $102.87 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Collegium Pharmaceutical, INC. | $100.03 | 2023-2025 | Belbuca, Xtampza |
| Upsher-Smith Laboratories LLC | $72.89 | 2019-2021 | |
| Ibsa Pharma INC. | $62.66 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $62.15 | 2024-2025 | |
| Kowa Pharmaceuticals America, INC. | $59.70 | 2022 | |
| Hikma Pharmaceuticals USA | $51.71 | 2022 | |
| Virtus Pharmaceuticals LLC | $49.40 | 2025 | Levorphanol Tartrate |
| Biodelivery Sciences International, INC. | $45.94 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $44.28 | 2023 | Quviviq |
| Tonix Medicines, INC. | $37.69 | 2025 | Tonmya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.75 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.67 | 2022 | |
| Medline Industries LP | $32.53 | 2020-2024 | |
| Nevro Corp. | $29.35 | 2022 | |
| Lilly USA, LLC | $26.30 | 2019-2020 | |
| Fidia Pharma USA INC. | $23.89 | 2020 | |
| Grt US Holding, INC. | $23.37 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $19.49 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.84 | 2019 | |
| Zimmer Biomet Holdings, INC. | $15.51 | 2022 | |
| Pacira Therapeutics, INC. | $14.77 | 2019 | |
| Pear Therapeutics (US), INC. | $14.68 | 2021 | |
| Nalu Medical, INC. | $13.28 | 2021 | |
| Saluda Medical Americas, INC. | $9.54 | 2024 | Evoke |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Overton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.